The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

We aim to assess the the efficiency and safety of N-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Treatments: Acetylcysteine; Busulfan; Cyclophosphamide; Cytarabine; N-monoacetylcystine

Criteria

Inclusion Criteria:

1. Aged 16-70 years old

2. Diagnosed as myeloid malignancies, and about to undergo allo-HSCT;

3. ECOG: 0-2;

4. Expected survival longer than 1 month

Exclusion Criteria:

1. Allergic to any components of NAC;

2. Severe dysfunction of heart, liver, lung and kidney;

3. Relapse before HSCT;

4. A history of bronchial asthma, bronchospasm or moderate / severe gastrohelcosis.